Amikacin/fosfomycin inhalation system - Cardeas

Drug Profile

Amikacin/fosfomycin inhalation system - Cardeas

Alternative Names: AFIS; Amikacin/fosfomycin eFlow® Nebulizer system; eFlow Inline System

Latest Information Update: 18 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardeas Pharma
  • Class Aminoglycosides; Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pneumonia
  • No development reported Bronchitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Bronchitis in Australia (Inhalation, Aerosol)
  • 01 Jul 2016 Cardeas Pharma completes a phase I pharmacokinetic trial in Healthy volunteers in USA (NCT02709265)
  • 01 Apr 2016 Cardeas Pharma initiates enrolment in a phase I pharmacokinetic trial in Healthy volunteers in USA (NCT02709265)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top